VONVENDI is used in adults (age 18 years and older) diagnosed with von Willebrand disease to:
treat and control bleeding episodes
prevent excessive bleeding during and after surgery
Who should not use VONVENDI?
You should not use VONVENDI if you:
Are allergic to any ingredients in VONVENDI
Are allergic to mice or hamsters
VONVENDI Prescribing Information
Baxalta receives FDA Approval for VONVENDI, the first and only recombinant treatment for adults affected by von Willebrand disease. Business Wire. December 8, 2015. Accessed July 9, 2020. https://www.businesswire.com/news/home/20151208006689/en/Baxalta-Receives-FDA-Approval-VONVENDIRecombinant-Treatment
Franchini M, Mannucci PM. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease. Expert Rev Hematol. 2016;9(9):825-830.
You're now leaving this site
Takeda does not review, endorse, or control the content of any non-Takeda site. Takeda is not responsible for the accuracy, content, practices, or standards of any non-Takeda resources accessed through a link on this site.